The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: A randomized, double-blind, placebo-controlled, crossover trial

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 6, 2005, Pages 547-555

  Dickman, R ^a   Emmons, S ^a   Cui, H ^b   Sewell, J ^a   Hernandez D ^a   Esquivel, R F ^a   Fass, R ^a,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THORAX PAIN; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CHEST PAIN; DOUBLE-BLIND METHOD; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; SENSITIVITY AND SPECIFICITY;

EID: 25444526385     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02620.x     Document Type: Article

References (37)

1. Eslick GD, Pass R. Noncardiac chest pain: evaluation and treatment. Gastroenterol Clin North Am 2003; 32: 531-52.
2. Ofman JJ, Gralnek IM, Udani J, Fennerty MB, Pass R. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999; 107: 219-27.
3. Eslick GD, Talley NJ, Young LJ, et al. Abstract: non-cardiac chest pain in the population: prevalence and impact. J Gastroenterol Hepatol 1999; 14: A179.
4. Richter JE, Bradley LA, Castell DO. Oesophageal chest pain: current controversies in pathogenesis, diagnosis and therapy. Ann Intern Med 1989; 110: 66-78.
5. Eslick GD, Talley NJ. Non-cardiac chest pain: squeezing the life out of the Australian healthcare system? Med J Aust 2000; 173: 233-4.
6. Beedassy A, Katz PO, Gruber A, Peghnini PL, Castell DO. Prior sensitization of oesophageal mucosa by acid reflux predisposes to reflux-induced chest pain. J Clin Gastroenterol 2000; 31: 121-4.
7. Frobert O, Funch-Jensen P, Jacobsen NO, Kruse A, Bagger JP. Upper endoscopy in patients with angina and normal coronary angiogram. Endoscopy 1995; 27: 365-70.
8. Hsia OC, Maher KA, Lewis JH, Cattau EL Jr, Fleischer DE, Benjamin SB. Utility of upper endoscopy in the evaluation of noncardiac chest pain. Gastrointest Endosc 1991; 37: 22-6.
9. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole patients with noncardiac chest pain. Gastroenterology 1998; 115: 42-9.
10. Hewson EG, Sinclair JW, Dalton CB, Richter JE. Twenty-four-hour oesophageal pH monitoring: the most useful test for evaluating noncardiac chest pain. Am J Med 1991; 90: 576-83.
11. Janssens J, Vantrappen G, Ghillebert G. 24-hour recording of oesophageal pressure and pH in patient with noncardiac chest pain. Gastroenterology 1986; 90: 1978-84.
12. de Caestecker JS, Blackwell JN, Brown J, Heading RC. The oesophagus as a cause of recurrent chest pain: which patients should be investigated and which tests should be used? Lancet 1985; 2: 1143-6.
13. Achem SR, Kolts BE, Richter JE, et al. Abstract: treatment of acid related non-cardiac chest pain: a double blind placebo controlled trial of omeprazole vs. placebo. Gastroenterology 1993; 104: A29.
14. Euler AR, Byrne WJ. Twenty-four hour oesophageal intraluminal pH probe testing: a comparative analysis. Gastroenterology 1981; 80: 957-61.
15. Richter JE, Castell DO. Gastroesophageal reflux, pathogenesis, diagnosis, and therapy. Ann Intern Med 1982; 97: 93-103.
16. Jamieson JR, Sten HJ, DeMeester TR, et al. Ambulatory 24-h oesophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol 1992; 87: 1102-11.
17. Bautista J, Fullerton H, Briseno M, Cui H, Fass R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain - a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2004; 19: 1123-30.
18. Vakil N. Review article: test and treat or treat and test in reflux disease? Aliment Pharmacol Ther 2003; 17: 57-9.
19. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic oesophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
20. Wiener GJ, Richter JE, Copper JB, Wu WC, Castell DO. The symptom index: a clinically important parameter of ambulatory 24-hour oesophageal pH monitoring. Am J Gastroenterol 1988; 83: 358-61.
21. Fass R, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999; 159: 2161-8.
22. Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 2000; 18: 20-6.
23. Rodriguez SL, Robinson M, Earnest DL, et al. Abstract: oesophageal hypersensitivity: a major cause of heartburn. Gastroenterology 1997: 112: A270.
24. Kahrilas PJ, Dodds WJ, Hogan WJ, Kern M, Arndorfer RC, Reece A. Oesophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology 1986; 91: 897-904.
25. Pandak WM, Arezo S, Everett S, et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour oesophageal pH monitoring. J Clin Gastroenterol 2002; 35: 307-14.
26. Xia HH, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patient with non-cardiac chest pain. Aliment Pharmacol Ther 2003; 17: 369-77.
27. Robinson M. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors - overview and clinical implications. Aliment Pharmacol Ther 2004; 20: 1-10.
28. Squillace SJ, Young MF, Sanowski RA. Abstract: single dose omeprazole as a test for noncardiac chest pain. Gastroenterology 1993; 107: A197.
29. Young MF, Sanowski RA, Talberts GA, et al. Abstract: omeprazole administration as a test for gastroesophageal reflux. Gastroenterology 1992; 102: 192.
30. Pass R, Pulliam G, Hayden CW. Abstract: patients with non-cardiac chest pain (NCCP) receiving an empirical trial of high dose lansoprazole, demonstrate early symptom response - a double blind, placebo-controlled trial. Gastroenterology 2001; 120: A221.
31. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease. Ann Intern Med 2004; 140: 518-27.
32. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.
33. Wong WH, Huang JQ, Zheng GF, et al. Is PPI test an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? A meta-analysis. Arch Intern Med 2005; 165: 1222-8.
34. Dekel R, Martinez-Hawthorne SD, Guillen RJ, Pass R. Evaluation of symptom index in identifying gastroesophageal reflux disease-related noncardiac chest pain. J Clin Gastroenterol 2004; 38: 24-9.
35. Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997; 42: 2138-45.
36. Singh S, Richter JE, Hewson EG, Sinclair JW, Hackshaw BT. The contribution of gastroesophageal reflux to chest pain in patients with coronary artery disease. Ann Intern Med 1992; 117: 824-30.
37. Stahl WG, Beton RR, Johnson CS, et al. Abstract: high dose ranitidine in the treatment of patients with noncardiac chest pain and evidence of gastroesophageal reflux disease. Gastroenterology 1992; 102: A168.